We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




EraGen and Bayer in License Agreement

By HospiMedica staff writers
Posted on 21 Jun 2005
EraGen Biosciences (Madison, WI, USA) has licensed its patented MultiCode-PLx system to Bayer HealthCare, Diagnostics Division (Tarrytown, NY, USA), in an exclusive worldwide agreement for cystic fibrosis (CF).

EraGen's MultiCode-PLx platform is a cost-effective, high-throughput genotyping system that simultaneously tests for predetermined mutations of the gene associated with cystic fibrosis, the cystic fibrosis transmembrane conductance regulator (CFTR) gene. More...
By leveraging isobases, the test substantially reduces the time for CF multi-mutation analysis compared to other testing systems. The test will allow the customers of Bayer Healthcare to enhance their level of CF clinical testing by reducing errors, providing faster turnaround, and lessening labor needs.

"Automated genetic diagnostics assays, including those for cystic fibrosis, are vital for the laboratory to take advantage of clinical progress, while maintaining lab efficiencies and providing timely, reliable clinical information,” stated Tony Bihl, president of Bayer HealthCare's Diagnostics Division.

The agreement between EraGen and Bayer also provides Bayer with additional rights, enabling the company to expand its presence in the genetics-based diagnostic testing market with a number of assays for other diseases.





Related Links:
EraGen
Bayer Diag.

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.